Arbutus Biopharma Corporation has grown revenue 98% a year over three years and 85% a year over five. Revenue growth, 3-year annual rate: +98% (Biotechnology median +17%). Revenue growth, 5-year rate: +85%, growth has picked up over the last three years. Years of annual history on file: 16, FY2010 to FY2025, as filed.

ABUSArbutus Biopharma Corporation

Healthcare

$4.18-2.7% 1Y

$4.18

$3.6752 weeks$5.20

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +1079% year on year and operating margin widening (+323.8 points), but earnings down −372% year on year.

2 good, 1 to watch

Revenue trend+1079% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +85% a year.

Earnings trend−372% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+323.8 points operating

Trailing-twelve-month operating margin, -658.5% now against -982.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ABUS growing?

Arbutus Biopharma Corporation has grown revenue 98% a year over three years and 85% a year over five.

+98%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +85%
Revenue growth, 5-year rate · +98% over three · growth has picked up over the last three years
Years of annual history on file: 16
Years of annual history on file · FY2010 to FY2025, as filed

Details›